IndustryCompany release

Addex spin-out Neurosterix closes $105M Series B to fund Phase 2 of schizophrenia drug NTX-253

Addex Therapeutics Ltd. (ADXN) · Thu 12 Nov 2026

Neurosterix, the 2024 spin-out of Addex Therapeutics, closed a $105 million Series B round from life science investors, announced on November 11, 2026. Proceeds will mainly fund Phase 2 development of NTX-253, an oral M4 positive allosteric modulator for schizophrenia, and the company's wider neuropsychiatric pipeline. Addex did not take part, and its stake is now 8.5%, valued at $18.6 million.

Company's press release (SEC filing): Addex Therapeutics Ltd. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →

IndustryCompany release

Addex spin-out Neurosterix closes $105M Series B to fund Phase 2 of schizophrenia drug NTX-253

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Helus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises

IM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel

DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing

Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient

Lifeward Q3 revenue falls 12% as AlterG grows and ReWalk moves to channel partners